Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13053)	1/7/1998 11:55:00 AM
From: Flagrante Delictu	Read Replies (2) \| Respond to of 32384

Henry, >>psoriasis & Panretin trials<< Thanks for the elucidation on both the skin disease & the choice of the more difficult route in the APL trials. We can be sure LGND management knows what they are about, based on their remarkable achievments to date. I have wondered about their use of both Targretin & Panretin against the same targets but thought that each compound might attack the problem from a different receptor or area of a receptor complex, enabling a different but complementary benefit to the patient. Would that were so, the revenue stream wouldn't hurt. Whatever happens, let's hope we get strong performing compounds to the market as soon as possible. Lastly, I've run into a roadblock on admission to the H & Q conference. I have plane tix & hotel reservations. If any threadster has a connection, I'd appreciate it. A comprehensive report of the LGND & whatever other of the presenting companies requested would be forthcoming. Bernie.